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Abstract  The  purpose  of  this  study  was  to  investigate  the  efﬁcacy  of  neurofeedback,  pharma-
cological  treatment  and  behavioral  therapy  in  Attention  Deﬁcit  Hyperactivity  Disorder  (ADHD)
through  a  controlled,  randomized,  multigroup  design,  with  pre-,  post-  and  follow-up  treat-
ment phases.  The  objectives  of  this  study  are:  a)  to  analyze  individual  trajectories  over  time
of each  child  in  treatment,  from  speciﬁc  measures  of  EEG  (theta/beta  ratio/TBR)  considering
age and  sex  and  b)  to  determine  the  therapeutic  effect  on  attentional  and  behavioral  variables
evaluated  through  the  Integrated  Visual  and  Auditory  Continuous  Performance  Test.  A  total  of
57 children  (7-14  years)  diagnosed  with  ADHD,  were  randomly  assigned  to  one  of  the  follow-
ing experimental  conditions:  1)  30  Theta/Beta  training  sessions,  2)  Methylphenidate  treatment
and, 3)  Behavior  therapy  administered  according  to  a  cognitive-behavioral  protocol  based  on
manuals. Data  were  analyzed  using  a  Multilevel  Longitudinal  Regression  Model.  Results  show
that administered  treatments  are  effective  and  cause  similar  effects  on  TBR  variable,  with
no differences  between  them.  However,  signiﬁcant  differences  were  observed  in  the  global
attention (p=.002),  auditory  attention  (p=.017)  and  visual  attention  (p=.028).
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Neurofeedback,  tratamiento  farmacológico  y  terapia  de  conducta  en  hiperactividad:
análisis  multinivel  de  los  efectos  terapéuticos  en  electroencefalografía
Resumen  Se  investiga  la  eﬁcacia  del  neurofeedback,  tratamiento  farmacológico  y  terapia  de
conducta en  el  Trastorno  por  Déﬁcit  de  Atención  con  Hiperactividad  (TDAH)  mediante  un  disen˜o
multigrupo, aleatorizado  y  controlado  con  fases  pre,  post-tratamiento  y  seguimiento.  Se  pre-
tenden los  siguientes  objetivos:  a)  analizar  las  trayectorias  individuales  a  través  del  tiempo,
de cada  nin˜o  en  tratamiento,  en  la  medida  del  EEG  (theta/beta  ratio/TBR),  considerando  edad
y sexo,  y  b)  determinar  el  efecto  terapéutico  en  variables  atencionales  y  conductuales  evalu-
adas mediante  el  Integrated  Visual  and  Auditory  Continuous  Performance  Test.  Participaron  57
nin˜os (7-14  an˜os)  diagnosticados  con  TDAH,  asignados  aleatoriamente  a  alguna  de  las  siguientes
condiciones  experimentales:  1)  30  sesiones  de  entrenamiento  theta/beta,  2)  tratamiento  con
metilfenidato  y  3)  terapia  de  conducta,  según  protocolo  basado  en  manuales.  Se  ha  empleado
el Modelo  Longitudinal  de  Regresión  Multinivel  para  análisis  de  datos.  Los  resultados  muestran
que los  tratamientos  administrados  son  eﬁcaces  y  originan  efectos  similares  en  la  variable  TBR,
no apreciándose  diferencias  entre  los  mismos.  Si  bien,  se  observan  diferencias  signiﬁcativas  en
la atención  global  (p=.002),  atención  auditiva  (p=.017)  y  atención  visual  (p=.028).
© 2015  Asociación  Espan˜ola  de  Psicología  Conductual.  Publicado  por  Elsevier  España,  S.L.U.
Este es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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bAttention  deﬁcit  hyperactivity  disorder  (ADHD)  is  a
eurodevelopmental  disorder  which  essential  feature  is
 persistent  pattern  of  inattention,  and/or  hyperactivity-
mpulsivity  that  interferes  with  functioning  or  development
American  Psychiatric  Association,  APA,  2013).  Phar-
acological  treatment  is  the  option  that  is  usually
ecommended  for  school-age  children  and  young  peo-
le  with  severe  ADHD  (NICE,  2013).  Empirical  studies
ave  generally  compared  the  efﬁcacy  of  pharmacologi-
al  treatment  with  other  therapy  options.  With  respect
o  behavioral  interventions,  So,  Leung,  and  Hung  (2008)
ndicated  that  the  combination  of  methylphenidate  and
ehavioral  therapy  was  effective  in  reducing  ADHD  symp-
oms  and  that  this  combination  favors  a  reduction  of
he  initially  prescribed  dose  of  medication  and  increases
arent  acceptance  of  treatment.  Sibley,  Kuriyan,  Evans,
axmonsky,  and  Smith  (2014)  concluded  that  medication
nd  behavior  therapy  produce  similar  range  of  ther-
peutic  effects  on  the  symptoms  of  adolescents  with
DHD.
Research  on  non-pharmacological  interventions  in
DHD  treatment  has  shown  that  psychological  treatments
hat  incorporate  behavioral  techniques  prove  effective.
odgson,  Hutchinson,  and  Denson  (2014)  replicated  the
ork  by  Fabiano  et  al.  (2009),  corroborating  the  efﬁcacy
f  seven  non-pharmacological  interventions  that  included
ehavioral  modiﬁcation,  neurofeedback,  school  programs
nd  parent  training.  Speciﬁcally,  there  is  clear  evidence
f  the  effects  of  parent  training,  whose  interventions
hould  be  tried  before  medication  among  preschoolers
ith  ADHD  and  results  remain  even  after  intervention
nded  (Charach  et  al.,  2013).  Thus,  parent  training
rograms  are  part  of  standard  treatments  for  children
ith  ADHD  (Storebø,  Gluub,  Winkel,  &  Simonsen,  2012),
s  well  as  school-based  interventions  (Evans,  Schultz,
eMars,  &  Daves,  2011).  Besides,  cognitive-  behavioral
nterventions  provide  satisfactory  results  when  applied
i
t
so  adolescents  with  ADHD  (Antshel,  Faraone,  &  Gordon,
014).
In  terms  of  neurofeedback,  the  statistically  signiﬁcant
esults  in  the  study  by  Hodgson  et  al.  (2014)  show  that  this
herapeutic  option  is  effective  at  reducing  ADHD  symptoms.
he  debate  on  the  evidence  of  neurofeedback’s  efﬁcacy
as  been  of  particular  interest  in  the  past  years  (Loo  &
akeig,  2012).  In  these  studies,  authors  have  focused  on
he  level  of  clinical  efﬁcacy,  which  has  been  determined  to
e  ‘‘Efﬁcacious  and  Speciﬁc’’  according  to  Arns,  De  Ridder,
trehl,  Breteler,  and  Coenen  (2009)  and  ‘‘Probably  Efﬁ-
acious’’  by  Lofthouse,  Arnold,  Hersch,  Hurt,  and  deBeus
2012).
In a study  by  Duric,  Assmus,  Gundersen,  and  Elgen  (2012)
uthors  concluded  that  neurofeedback  represents  a  viable
lternative  to  pharmacological  treatment.  Following  Willis,
eyandt,  Lubiner,  and  Schubart  (2011),  who  reviewed  the
mpirical  works  published  between  2004  and  2010,  and  the
tudies  published  between  1994  and  2010  it  is  considered
hat  the  evidence  on  the  efﬁcacy  of  neurofeedback  is  still
ot  conclusive.
Electrophysiological  measures  were  among  the  ﬁrst  to
e  used  to  study  brain  processes  in  children  with  ADHD.
articularly,  electroencephalography  (EEG)  has  been  used
oth  in  research,  to  describe  and  quantify  the  under-
ying  neurophysiology  of  ADHD,  but  also  clinically,  in
he  assessment,  diagnosis  (González-Castro,  Rodríguez,
ópez,  Cueli,  &  Alvarez,  2013)  and  treatment  of  ADHD.
ncreased  theta/beta  ratio  (TBR)  has  show  to  be  a
ensitive  marker  of  ADHD  (Monastra,  Lubar,  &  Linden,
001)  and  correlates  strongly  with  age-related  changes
n  ADHD  behavioral  symptomatology  overtime  (Snyder  &
all,  2006).  Given  the  excess  of  theta  and  decreased
eta  activity  observed  among  children  with  ADHD,  it
s  easy  to  understand  that  altering  these  parameters
hrough  treatment  would  result  in  improvements  in  ADHD
ymptoms.
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This  is  the  background  for  this  study,  which  aims  to  deter-
mine  the  efﬁcacy  of  three  well-known  alternative  therapies
on  ADHD  (neurofeedback,  pharmacological  treatment  and
behavioral  therapy),  each  administered  alone,  with  no  over-
lapping  treatments.  The  present  study  was  undertaken:  a)
to  analyze  individual  trajectories  over  time  of  each  child
in  treatment,  in  EEG  measure  (TBR  variable)  considering
age  and  sex,  b)  to  determine  the  therapeutic  effect  on
attentional  and  behavioral  variables  evaluated  through  the
Integrated  Visual  and  Auditory  Continuous  Performance  Test
(IVA/CPT)  (Sandford  &  Turner,  2000).
Method
Participants
Children  who  participated  in  the  study  were  chosen  through
pediatric  primary  care  consultations  at  the  Distrito  Sanitario
Sevilla  Sur  (Servicio  Andaluz  de  Salud,  Sevilla,  Spain).  Pedia-
tricians  applied  SNAP-IV  scale  (Swanson,  2003)  in  screening
phase.  Following  inclusion  criteria  were  considered:  1)
meeting  ADHD  diagnosis  criteria  according  to  DSM-V  (APA,
2013)  using  a  clinical  assessment  based  on  a  psychiatric
interview  for  parents;  the  Clinical  Interview  form  for  Child
and  Adolescent  ADHD  Patients  (Barkley,  1987);  and  get  a
score  above  the  90th percentile  on  The  ADHD  Rating  Scale-IV
(ADHD-RS)  (Teacher  Version)  and  above  the  80th percentile
on  the  parents’  version  (DuPaul,  Power,  Anastopoulos,  &
Reid,  1998);  2)  being  between  7  and  14  years  old;  3)
patients  being  drug-naïve  before  the  ﬁrst  consultation,  4)
not  present  comorbid  disorders  with  ADHD,  assessed  through
the  Child  Behavior  Checklist  for  Ages  6-18  (CBCL)  for  par-
ents  (Achenbach  &  Recorla,  2001)  and  5)  patients  with
no  history  of  medical  illness,  chronic  medical  illness  or
current  medical  illness.  Assessment  was  performed  by  psy-
chologists  that  conﬁrmed  compliance  with  such  criteria.
Initially  were  recruited  144  children,  52  infants  of  these
were  excluded  according  to  the  inclusion  criteria,  n  =  35
did  not  meet  diagnostic  criteria,  n  =  8,  age  <7  years  and
n  =  9  for  by  comorbid  medical  pathology.  92  children  were
selected,  and,  of  these,  n  =  35  declined  participation.  57
subjects  diagnosed  with  ADHD,  and  ages  7  to  14,  partici-
pated  in  the  study  (Table  1).  This  investigation  was  approved
by  the  Human  Research  Ethics  Committee  of  the  University
of  Sevilla.
Measures
In  the  following  phases  of  the  study,  attentional  and  behav-
ioral  variables  and  EEG  measures  of  all  participants  were
taken.
Electroencephalographic  evaluation  was  carried  out  with
the  team  Atlantis  II  2  ×  2  Clinical  System,  with  Brainmas-
ter  3.5.  Software,  using  a  monopolar  location  on  Cz  or  FCz
(based  on  the  International  10-20  system)  and  reference
in  the  earlobes.  We  proceeded  to  the  placement  of  elec-
trodes,  identifying  the  point  on  Cz  for  participants  between
7  and  11  years  old,  and  for  older  participants,  it  was  cal-
culated  at  FCz  (Thompson  &  Thompson,  2003).  Frequency
range  was  1  to  30  Hz,  with  a  sampling  rate  of  256  mps,
considering  the  threshold  artifact  of  ±  100  microvolts.  All
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lectrodes  were  adjusted  to  maintain  impedance  below
0  K.  Considered  bands  were,  Theta  (4-7  Hz),  Alpha  (8-
2  Hz),  Lowbeta  (12-15  Hz),  Beta  (15-20  Hz)  and  Highbeta
20-30  Hz).
After  explaining  the  procedure  to  participants,  we  pro-
eeded  to  carry  out  the  assessment,  remaining  children
itting  at  the  table,  in  which  the  four  tasks  proposed  of
 minutes  duration  were  performed.  Prior  to  each  task,  a
0  seconds  baseline  was  established.
Attentional  and  behavioral  variables  were  evaluated
hrough  the  Integrated  Visual  and  Auditory  Continuous  Per-
ormance  Test  (IVA/CPT)  (Sandford  &  Turner,  2000).  This
ool  evaluates  attention  and  response  control  to  auditory
nd  visual  stimuli.  This  test  can  be  administered  to  chil-
ren  (ages  6  and  older),  adolescents  and  adults.  This  test
as  been  administered  in  previous  studies  in  which  partic-
pated  Spanish  samples  (Moreno-García,  Delgado-Pardo,  &
oldán-Blasco,  2015).  In  this  research  we  analyzed  the  cor-
esponding  measures  of  the  visual  and  auditory  Attention
uotients  (Full  Scale  Attention  Quotient,  Visual  Attention
uotient  and  Auditory  Attention  Quotient)  and  visual  and
uditory  Response  Control  Quotients  (Full  Scale  Response
ontrol  Quotient,  Visual  Response  Control  Quotient  and
uditory  Response  Control  Quotient).
rocedure
his  was  a  randomized  controlled  study  with  a  multigroup
esign  to  determine  the  efﬁcacy  of  three  treatment  types:
eurofeedback,  standard  pharmacological  treatment  and
ehavioral  therapy,  with  pre,  post  and  follow-up  phases.
articipants  were  evaluated  individually  under  identical
onditions,  before,  during  and  after  therapeutic  interven-
ion.  Three  groups  with  the  same  number  of  participants
ere  randomly  conﬁgured.  No  pre-treatment  differences
ere  corroborated  for  any  of  the  participants.  The  random-
zation  was  done  according  to  a  random  number  chart  (San
artin  &  Pardo,  1989).
Random  numbers  were  assigned  in  each  case  sorted  by
erivation  and  study  entry.  After  parental  consent  was  given
along  with  oral  consent  from  all  children  over  the  age  of
2),  children  who  met  the  inclusion  criteria  were  randomly
ssigned  to  the  different  experimental  groups  (Table  1).
n  no  case  were  other  treatments  administered  simultane-
usly.
In each  phase,  the  evaluation  was  done  by  ‘‘blind’’  eval-
ators  who  were  not  aware  which  type  of  therapy  children
ad  received.  The  evaluation  conditions  were  identical  in
ll  three  phases  of  the  study.  Children  were  individually
ested  between  10  am  and  14  am  in  a  speciﬁc  room  isolated
rom  noise  and  distracting  events.  Pre-treatment  evaluation
as  done  approximately  one  week  before  treatment  began
nd  post-treatment  evaluation  was  done  when  intervention
as  complete,  in  all  cases  after  20  weeks  of  intervention.
ollow-up  evaluation  was  performed  within  two  months
pon  completion  of  the  three  intervention  groups,  namely,
ompleted  30  sessions  of  neurofeedback,  ended  behavioral
herapy  program  and  within  ﬁve  months  after  the  initiation
f  pharmacological  treatment  for  children  assigned  to  that
roup.
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Table  1  Demographic  and  clinical  characteristics  of  the  neurofeedback  group,  the  pharmacological  group  and  the  behavioral
therapy group.
Pharmacological  group
n= 19
Neurofeedback  group
n=  19
Behavioral  group
n=  19
Age  (M  ±  SD)  9.21±  2.2  9.21±  1.9  8.11±  1.3
SEX (boys/girls)  15/4  (78.94%/21.05%)  15/4  (78.94%/21.05)  14/5  (73.68%/26.31%)
IQ (K-BIT)
Crystallized  (Verbal)  101.70  ±  12.5  106.79  ±  12.8  100.81  ±  12
Fluid (Nonverbal)  93.3  ±  10.8  101.93  ±  11.8  97.94  ±  17.7
IQ Composite  94.70  ±  12.9  103.36  ±  13  96.94  ±  14.5
DSM V
Combined  presentation 8  (42.10%) 7  (36.84%) 5  (26.31%)
Inattentive  presentation  8  (42.10%)  8  (42.10%)  11  (57.89%)
Hyperactive-Impulsive  presentation  3  (15.78%)  4  (21.05%)  3  (15.78%)
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treatment  groups
 Pharmacological  treatment.  Patients  assigned  to  this
group  received  standard  ADHD  treatment  prescribed  by
pediatrician  in  accordance  with  Clinical  Practice  Guide-
line  recommendations  of  the  Spanish  National  Health
System  (2010)  for  ADHD  treatment  in  children  and  ado-
lescents.  All  patients  received  a  low  dosage  of  1  mg  per
kilo  a  day  of  methylphenidate  in  its  different  formulations
(immediate,  intermediate  release  and  OROS).  Since  this
is  a  standard  treatment,  pediatricians  responsible  have
applied  for  each  case,  weight  control,  height,  vital  signs,
side  effects,  adverse  event.
 Neurofeedback  training.  Was  conducted  using  Atlantis  II
2  ×  2  equipment  from  Brainmaster.  This  equipment  uses
an  impedance  check  (below  5  Kohms)  and  controls  arti-
facts  automatically  (>120  microvolts).  EEG  was  analyzed
in  two  frequency  bands  (theta:  4-7  Hz,  beta:  15-20  Hz),
coinciding  with  Meisel,  Servera,  Garcia-Banda,  Cardo,  and
Moreno  (2014).  Participants  received  4  theta/beta  train-
ing  sessions  per  week  for  a  total  of  30  sessions.  Each
session  lasted  24  minutes  and  consisted  of  six  four-minute
runs  and  was  preceded  by  a  30-second  initial  baseline.
During  training,  each  child  could  choose  between  ﬁve
different  screens  (games,  puzzles,  etc.)  including  immedi-
ate  auditory  feedback,  counter  points  accompanying  the
sound  and  an  animation  that  progressed  as  they  increased
the  points  earned.  Program  calculated  individual  thresh-
olds  according  to  daily  baseline  values,  and  had  the
following  reinforcement  plan:  participants  were  rewarded
for  70%  of  the  time  below  the  threshold  in  theta,  and  up
to  20%  of  the  time  below  the  threshold  in  beta.  Training
of  all  subjects  assigned  to  this  therapeutic  condition  was
conducted  by  the  same  therapist.
 Behavioral  therapy.  Intervention  based  on  behavioral
treatment  and  administered  in  the  MTA  (MTA  Cooperative
Group,  1999)  consisted  in  parent  training,  individualized
and  focused  treatment  for  children  assigned  to  this  group
and  teacher  training.  Speciﬁcally,  this  therapy  included  15
individualized  sessions  of  cognitive-behavioral  therapy  for
each  child,  each  lasting  50  minutes.  Parents  participated
in  10  weekly  90-minute  sessions  based  on  Parent  Training
u
o
aProgram  (Barkley,  1987),  and  teachers  had  5  group  sessions
of  90-minute  each  one,  focused  on  two  aspects:  a)  train-
ing  on  behavior  modiﬁcation  strategies  in  the  classroom  (3
sessions)  and  b)  speciﬁc  curricular  adaptations  for  ADHD
(2  sessions).  Adults  received  advice  on  implementing  and
reinforcing  the  behavior  strategies  acquired  at  home  and
at  school.
esults
ata  were  analysed  using  a  Multilevel  Longitudinal  Regres-
ion  Model  (MLM)  (Peugh,  2010)  (Objective  1).  Considering
he  three  study  phases  we  analyzed  3  waves  of  data,  being
he  values  of  the  time  variable  0,  5  and  13  respectively.  For
 better  comprehension,  the  data  were  clocked  in  months
n  order  to  assess  ‘‘monthly  rate  of  change’’.  To  study
he  evolution  of  TBR  overtime  (pre,  post  and  follow  up)
nd  the  effect  of  the  treatment  variable,  as  well  another
peciﬁc  subjects  (age,  sex)  we  proceeded  with  MLM  for  lon-
itudinal  analysis.  MLM  offers  several  advantages  (Bryk  &
audenbush,  1992).  We  mention  among  others  the  following.
irst,  we  have  growth  curves  different  for  each  subject.  Sec-
nd,  no  restrictions  are  assumed,  as  homoscedasticity  and
phericity.  Third,  missing  data  are  permitted  in  MLM  (no  nec-
ssary  for  all  subjects  to  have  three  occasions),  as  well,  can
iffers  the  timing  of  the  observations  (not  exact  timing  of
ata  collection).  And  fourth,  it’s  possible  to  add  higher  lev-
ls  and  investigate  the  effect  of  such  levels  (family,  school,
tc.)  on  individual  change.
An  analysis  of  variance  was  performed  (ANOVA)  (Objec-
ive  2)  and  the  subsequent  post-hoc  contrasts  between  the
reatments  were  made,  with  the  Bonferroni  correction  to
ontrol  the  alpha  error.  Before  the  analysis,  a Levenes´  test
as  used  to  assess  the  homogeneity  of  the  variance.  It  has
een  used  as  a  measure  of  efﬁcacy,  the  change  variable,
btained  from  the  mean  differences  of  each  treatment  in
he  three  measurements  (pre,  post-treatment  and  follow
p).  That  change  variable  was  considered  an  indicator  of  the
bserved  improvement  regarding  each  of  the  treatments.
All  treatments  mentioned  above  and  each  child  was
ssessed  3  times  (pre,  post  and  follow-up)  in  TBR
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Table  2  Mean  and  standard  deviation  of  TBR  for  the  three  points  of  assessment.
Pre-Treatment  Post-Treatment  Follow  up  Treatment
Treatments M  SD  M  SD  M  SD
Pharmacological  Treatment  2.69  0.44  2.34  0.40  2.32  0.36
Neurofeedback  2.79  0.84  2.61  0.55  2.36  0.63
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(Table  2).We  proceeded  with  multilevel  regression  anal-
ysis  in  three  parts.  Four  steps  of  this  process  (Table  3)
are  established:  Model  A.  Unconditional  model,  Model  B.
Intersections  random  model,  Model  C.  Sex  and  age  (as
explanatory  intersections  variables),  and  Model  D.  Treat-
ment  (as  an  explanatory  intersection  variable).
Change
We  elaborated  the  unconditional  model  (Model  A)  which
informs  us  that  the  average  population  estimation  for  the
dependent  TBR  variable  is  2.55.  It  is,  therefore,  a  value
signiﬁcantly  different  from  zero  (Table  3).  The  model:
TBR  =  2.54  +  u0 +  e.
Where  the  between-subjects  variance  is  0.23  and  the
within-subjects  variance  is  0.12,  both  statistically  sig-
niﬁcant.  The  value  of  0.23  informs  us  that  individual
trajectories  are  different.  According  to  these  estimations,
the  intraclass  correlation  coefﬁcient  has  a  value  of  .66.
  = 
2
u0
2u0 +  2e
= 0.23
0.23  +  0.12 =  .66
That’s  means  that  the  66%  of  the  variability  in  TBR  is  due
to  the  individuals.
Regarding  the  second  model  (Model  B)  we  introduce
the  Time  as  an  explanatory  variable:  TBR  =  2.72--0.11  *
Time  +  u0 +  e
At  the  beginning  of  the  treatment  (pre),  the  average
value  of  TBR  for  all  children  is  2.72  with  a  slope  of  -0.116
(p  <  .001).  On  average  (including  all  treatments)  the  sub-
jects  on  average  decrease  0.11  points  per  month  in  TBR  at
post  and  follow-up  considering  that  the  model  is  linear  and,
therefore,  the  slope  is  constant  for  all  values  (Table  3).
On  the  other  hand,  the  intercept  variance  (2u0 )  indicated
a  value  of  0.24  (p  <  .001),  but  the  slope  variance  (2u1 )  indi-
cated  a  value  of  0.002  (p  >  .05)  (Table  3).  This  means  that
individuals  vary  at  start  of  treatment  but  not  on  their  devel-
opment  over  time.  All  slopes  are  equal.  No  need  to  look
for  variables  that  explain  any  changes  in  such  slopes,  so  we
ignore  the  random  slopes  model.  Regarding  all  subjects,  a
negative  slope  is  observed,  showing  that  in  all  cases  TBR
decreases,  appreciating  that  all  the  lines  are  parallel,  so
that  administered  treatments  work  equally.  The  correlation
obtained  for  this  equation  is  .26  (p  =  .004),  and  the  propor-
tion  of  variation  explained  .262 =  0.07.  That  is,  R2
Y,Yˆ
=  .07.
We  concluded  that  7%  of  total  variability  in  TBR  is  associ-
ated  with  linear  Time  (Table  3).  We  can  also  compare  the
residual  variance  of  this  model  with  the  residual  variance  in
b
F
c2.43  0.53  2.38  0.65
he  unconditional  model  and  get  the  proportion  in  residual
ariance  as  a  measure  of  the  improvement  of  our  model:
2
e =
0.12  −  0.09
0.12
=  0.25
We  have  achieved  a 25.5%  improvement  including  into
he  regression  model  the  Time  variable.  We  concluded  that
5.5%  of  the  within-person  (ﬁrst  level)  variation  in  TBR  is
xplained  by  linear  Time.
Regarding  the  third  model  (Model  C),  Sex  and  Age  as
xplanatory  intersections  variables  are  introduced  at  the
econd  level.  No  explanatory  variables  for  the  slopes  are
ecessary:
TRB  =  2.83--0.36  *  Sex--0.08  *  Age--0.11  *  Time  +  u0 +  e
The  effect  of  Age  is  -0.08  (p  =  .001)  and  Sex  -0.36
p  =  .018).
Here,  2.83  is  the  average  value  for  the  boys  and  for  the
verage  value  of  age.  Regarding  the  girls,  on  average,  they
egin  -0.36  points  lower  than  boys,  but  they  beneﬁt  the
ame  from  treatment,  being  development  identical  for  all,
s  shown  in  the  constant  slope,  differing  at  intersections.
The  age  is  also  signiﬁcant  since  with  increasing  age,
ecreases  TBR  in  -0.085  points  on  average  per  year  of  age  in
hildren  (p=  .001).  Younger  children  have  TBR  higher  values.
In  the  same  way  as  before,  we  can  get  a  value  of  the
roportion  of  total  variation  explained  by  this  model  com-
uting  the  square  correlation  between  the  observed  and
redicted  values.  Here  R2
Y,Yˆ
=  .27.  Thus,  the  addition  of  Sex
nd  Age  has  the  following  improvement  over  Model  B:  Model
:  0.27--0.07  =  0.20,  that  is,  a  20.5%  of  the  total  of  variation
n  TBR  is  explained  by  Sex  and  Age.
Regarding  R2e,  no  new  predictor  variables  are  added  at  the
rst  level.  Comparing  with  the  starting  point  (model  A),  no
mprovement  we  have  achieved.  Thus,  it  remains  Re2 = .25.
In  a similar  way  at  the  ﬁrst  level,  we  can  compute  the
mprovement  of  the  residual  variances  at  the  second  level.
e  can  distinguish  residual  intercept  variance  (2u0 )  and
esidual  slope  variance  (2u1 ).  As  we  have  mentioned  resid-
al  slopes  variance  is  not  statistical  signiﬁcant,  thus  we  only
onsider  residual  intercept  variance.  In  this  sense:
2
0 =
0.24  −  0.18
0.24
=  0.24
Including  Sex  and  Age,  we  concluded  that  24.8%  of  the
etween-person  (second  level)  variation  in  TBR  is  explained
y  Sex  and  Age  (Table  3).
In  the  fourth  model  (Model  D)  we  add  the  treatments.
or  this  categorical  variable  of  three  levels  (pharmacologi-
al,  neurofeedback  and  behavioral)  we  need  two  dummies
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ariables,  in  this  case  with  the  following  code:  neurofeed-
ack  (0,  0),  pharmacological  (1,  0)  and  behavioral  (0,  1):
RB  =  2.88--0.38  * Sex--0.10 *  Age  +  0.09  *  Pharma--0.18  *
eha--0.11  * Time  +  u0 +  e.
The  value  2.88  is  the  average  point  in  TRB  for  boys,  age
centered)  and  neurofeedback  treatment.  Pharmacological
reatment  have  0.09  point  less  than  neurofeedback  treat-
ent  (p  =  .577)  and  behavioral  treatment,  0.18  points  less
han  neurofeedback  (p=.308).  On  the  other  hand,  Sex  and
ge  have  the  same  signiﬁcation  as  before.
In  order  to  know  the  distance  between  behavioral  treat-
ent  and  the  other  treatments,  we  use  the  following  code:
ehavioral  (0,  0),  pharmacological  (1,  0)  and  neurofeedback
0,  1).  In  this  case:  TRB  =  2.70--0.38  *  Sex--0.10 * Age  +  0.27
 Pharma  +  0.18  *  Neuro--0.11  * Time  +  u0 +  e.
Pharmacological  treatment  have  0.27  point  more  than
ehavioral  treatment  (p  =  .082)  and  neurofeedback  treat-
ent,  0.18  points  (as  expected)  more  than  behavioral
p  =  .308).  No  change  in  Sex  and  Age.
Now,  the  proportion  of  total  variation  explained  for
odel  D  is  R2
Y,Yˆ
=  .30.  The  improvement  over  Model  C  is
.30--0.27  =  0.03,  indicative  that  the  treatments  do  not  add
uch  variability  because  they  are  equal  to  each  other.  In
act,  the  residual  intercept  variance  (2u0 )  is  the  same  as
odel  C.  The  residual  intercept  variance  is  0.18,  the  same
s  model  C.  No  improvement  due  to  treatment  at  the  second
evel.
Regarding  the  second  objective,  the  analysis  of  variance
hows  that  there  are  signiﬁcant  differences  between  treat-
ents  in  the  three  attentional  variables  studied  (Table  4)
ull  Scale  Attention  F(2,  23)  =8.65,  p=.002,  Auditory  Atten-
ion  Quotient  F(2,  32)  =4.63, p=.017  and  Visual  Attention
uotient  F(2,  23)  =4.19,  p=.028.  No  signiﬁcant  changes  were
bserved  in  behavioral  control  measures  evaluated.  The
ost  hoc  analyzes  showed,  in  the  variable  Full  Scale  Atten-
ion  that  pharmacological  treatment  (M  =  28.57,  SD  = 11.67)
ets  better  results  than  neurofeedback  (M  =  2.10,  SD  = 16.88)
(2,  23)=  4.03,  p=.002  and  behavior  therapy  (M  =  3.88,
D  =  16,24),  F(2,  23)  =  3.17,  p=.013.  This  improvement  is
lso  seen  in  the  variable  related  with  auditory  attention
Auditory  Response  Control  Quotient),  being  pharmacolog-
cal  therapy  (M  =  22.44,  SD  =  17.77)  more  effective  than
eurofeedback  (M  =  3.61,  SD  =  19.90)  F(2,  32)  =  3.03,  p=.014.
owever,  without  signiﬁcant  difference  between  pharmaco-
ogical  therapy  and  behavior  therapy  (M  =  5.92,  SD  =  20.86)  F
2,  32)  =  1.92,  p=.188.  Regarding  the  variable  that  indicates
isual  attention  such  as,  (Visual  Response  Control  Quo-
ient),  pharmacological  treatment  signiﬁcantly  improve,
ompared  with  neurofeedback  (M=0.60,  SD  =  18.19)  F(2,
3)  =  2.58,  p=.050  and  behavior  therapy  (M=0.22,  SD  =  20.97)
(2,  23)  =  2.56,  p=.052.
Treatment  differences  observed  in  attentional  varia-
les  in  post-treatment  are  not  maintained  in  follow-up
hase.  Full  Scale  Attention  F(2,  21)  =  1.26,  p=.302,  Auditory
esponse  Control  Quotient  F(2,  27)  =  1.28,  p=.292  and  Visual
esponse  Control  Quotient  F(2,  21)  =  998, p=.385.iscussion
ccording  to  previous  studies,  TBR  can  be  used  to  deter-
ine  treatment  effects  on  ADHD  symptomatology,  such
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Table  4  Analysis  of  the  differences  between  groups,  Pre-Treatment  and  Post-Treatment,  Neurofeedback,  Pharmacological
Treatment  and  Behavior  Therapy  for  the  attentional  variables  and  for  the  variables  related  to  response  control  of  the  IVA/CPT
(Sandford &  Turner,  2000).
Pharmacological
Treatment
Neurofeedback  Behavior  Therapy
M  SD  M  SD  M  SD  F  p
IVA/CPT  Change  variable
Full  Scale  Response  Control  Quotient  -7.85  20.84  3.50  22.99  -1.88  10.43  0.74  .486
Auditory Response  Control  Quotient  8.60  20.90  1.92  22.16  -8.30  10.70  1.31  .283
Visual Response  Control  Quotient  -1.28  18.30  -0.40  25.38  3.88  15.07  0.15  .856
Full Scale  Attention  Quotient -28.57 11.67  2.10  16.88  -3.88  16.24  -8.65  .002**
Auditory Attention  Quotient -22.40 17.77 3.61 19.90 -5.92  20.86  4.63  .017*
Visual Attention  Quotient -24.71 17.28 -0.60 18.19 -0.22 20.91  4.19  .28*
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as  neurofeedback  and  pharmacological  treatment  (Clarke,
Barry,  Bond,  McCarthy,  &  Selikowitz,  2002).  We  analyzed
TBR  evolution  overtime  (pre,  post  and  follow  up)  in  chil-
dren  treated,  through  developed  multilevel  models.  Most
studies  about  this  subject  analyze  current  treatments  effec-
tiveness  for  ADHD  comparing  between  two  therapeutic
choices,  being  frequent  comparison  between  pharmacothe-
rapy  and  psychosocial  treatments  (Oord,  Prins,  Oosterlaan,
&  Emmelkamp,  2008).  However,  there  are  few  studies
comparing  behavioral  therapy  regarding  neurofeedback
(Hodgson  et  al.,  2014)  and  actually  there  are  no  studies  con-
trasting  the  effects  of  these  three  treatments  administered
individually  from  multilevel  analysis.
In  this  study,  we  analyze  three  treatments  effects
(pharmacological  treatment,  behavioral  therapy  and  neu-
rofeedback)  administered  individually.  From  selection  of
speciﬁc  multilevel  models,  proposed  to  analyze  variables
from  different  levels  simultaneously  has  been  possible  to  see
TBR  evolution  in  time  of  each  child  who  has  been  treated,
comparing  individual  trajectories,  and  searching  whether
personal  variables  considered  such  as  sex,  age  or  type  of
treatment  given,  could  explain  TBR  evolution  observed  in
subjects.
Results  obtained  by  measuring  TBR  show  that  chil-
dren  who  received  treatment  for  ADHD  vary  positively
and  similarly  in  their  TBR  evolution  overtime  as  a  result
of  treatment,  and  do  so  regardless  of  type  of  treatment
(pharmacological  treatment,  behavioral  therapy  or  neuro-
feedback)  received.
These  ﬁndings  are  in  agreement  with  previous  studies
showing  similar  results  when  carried  pair  wise  compar-
isons  between  treatments.  Meisel  et  al.  (2014)  described
that  similar  improvements  are  achieved  by  pharmacological
treatment  and  neurofeedback  in  the  overall  functioning  of
children,  according  to  parents,  and  reducing  ADHD  primary
symptoms  according  to  parents  and  teachers.  Our  results
coincide  with  that,  although  it  must  be  noted  that  in  this
case,  the  improvement  has  been  observed  by  the  downward
trend  of  TBR.  They  are  also  consistent  with  results  obtained
by  Clarke  et  al.  (2002)  showing  that  pharmacological  treat-
ment  reduces  TBR.
Regarding  comparative  effects  between  behavioral  ther-
apy  and  neurofeedback,  Hodgson  et  al.  (2014), in  their
c
d
hnd Post-Treatment means.
eta-analysis,  showed  the  effectiveness  of  these  options,
specially  in  girls,  although  data  differ  according  to  used
ffectiveness  measures.  Results  coincide  with  Van  der  Oord,
rins,  Oosterlaan,  &  Emmelkamp  (2008)  and  disagree  with
harach  et  al.  (2013). First  investigation  concluded  that
harmacological  treatment  is  as  effective  as  psychosocial
reatment  considering  academic  performance  and  social
ehavior  of  ADHD  children.  However,  Charach  et  al.  (2013)
ound  that  parent  training  was  more  effective  than  pharma-
ological  treatment  when  intervention  was  developed  with
re-school  children.
Given  gender  variable,  as  shown  by  data  obtained,  vari-
bility  exists  between  boys  and  girls  at  the  beginning  of
reatment.  Girls  even  when  they  start  with  lower  scores,
eneﬁt  from  the  same  treatments  as  boys,  since  TBR  evo-
ution  overtime  is  parallel  to  that  observed  in  opposite  sex
eers,  because  no  differences  between  them  can  be  seen  in
traight  or  on  the  slopes  of  each,  showing  that  TBR  evolution
s  the  same  for  all  subjects.
Consistent  with  these  ﬁndings,  Clarke,  Barry,  Mc  Carthy,
nd  Selikowitz  (2001)  found  differences  between  EEG  mat-
ration  in  normal  children.  Girls  compared  with  boys  had
 delayed  maturation,  although  this  delay  tended  to  disap-
ear  in  adolescence.  Results  of  this  study  indicate  that,  with
dministered  treatments,  without  differentiating  between
hem,  gender  differences  found  at  the  beginning  of  the
ntervention  in  the  pre-treatment  phase  are  homogenized.
On  the  other  hand,  results  indicate  that  age  inﬂuences
hanges  in  TBR,  namely,  TBR  decreases  while  increasing
ge  of  children  who  received  treatment.  These  results
re  consistent  with  previous  studies  in  normal  population
Bresnahan  &  Barry,  2002) but,  in  this  case,  studied  subjects
ere  children  with  ADHD.  They  also  agree  with  Clarke  et  al.
2001),  showing  that  children  and  adolescents  with  ADHD
ave  a  higher  TBR  compared  with  normal  children,  which
s  reduced  over  time.  Ogrim,  Kropotov,  and  Hestad  (2012),
ound  that  TBR  was  higher  in  younger  than  older  being  age
ffect  most  signiﬁcant  in  children  with  ADHD  than  in  con-
rol  subjects.  Results  demonstrate  that  inﬂuence  of  age  is
onsistent  with  TBR  changing.
The  results  show  that  the  three  investigated  treatments
id  not  differ  in  behavioral  control.  Although  no  studies
ave  been  published  to  date  comparing  the  effects  of  the
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hree  treatments  administered  individually,  Duric  et  al.
2012)  considering  others  reports  and  behavioral  scales,
howed  that  neurofeedback  is  a  treatment  as  effective  as
ethylphenidate.  Related  to  visual  and  auditory  attention
e  found  that  pharmacological  treatment  is  more  efﬁ-
acious  than  neurofeedback,  while  behavior  therapy  and
harmacological  treatment  improves  attention  to  auditory
timuli  in  a  similar  way.
A  limitation  of  this  work  is  the  lack  of  previous  studies
ith  multilevel  analysis  methodology  that  reduced  the  pos-
ibilities  of  contrast  and  discussion  of  results.  It  remains  for
uture  research  to  increase  the  number  of  studied  children
nd  to  perform  similar  studies  expanding  the  study  varia-
les.
Finally,  it  would  be  interesting  to  explore  the  possibil-
ties  of  individualized  application  of  neurofeedback  alone
nd  also  combined  with  behavioral  therapy  for  ADHD,  and
o  analyze,  speciﬁcally,  neurofeedback  impact  in  child  func-
ioning.  In  addition,  it  would  be  important  to  compare  the
fﬁcacy  of  each  of  the  treatments  studied  in  relation  to  both
exes.
unding
his  research  study  has  been  funded  by  Plan  Nacional  i  +  d  +  i
National  Research,  Development  and  Innovation  Program)
PSI2008--06008-C02--01).
eferences
chenbach, T. M., & Recorla, L. A. (2001). Manual for the ASEBA:
Forms & Proﬁles of CBCL (6-18).  Burlington. VT: University of
Vermont.
merican Psychiatric Association. (2013). Diagnostic and Statistical
Manual of Mental Disorders (5th SEPARAR ed.). Washington DC:
American Psychiatric Publishing.
ntshel, M. K., Faraone, V. S., & Gordon, M. (2014). Cognitive
behavioral treatment outcomes in adolescent ADHD. Jour-
nal of Attention Disorders, 18,  483--495. http://dx.doi.org/
10.1177/1087054712443155
rns, M., De Ridder, S., Strehl, U., Breteler, M., & Coenen,
A. (2009). Efﬁcacy of neurofeedback treatment in ADHD:
The effects on inattention, impulsivity, and hyperactivity. A
meta-analysis. Clinical EEG and Neuroscience, 40,  180--189.
http://dx.doi.org/10.1177/155005940904000311
arkley, R. B. (1987). Deﬁant children: A clinician manual for parent
training. New York: Guilford Press.
resnahan, S. M., & Barry, R. J. (2002). Speciﬁcity of quantita-
tive EEG analysis in adults with attention deﬁcit hyperactivity
disorder. Psychiatry Research, 112, 133--144.
ryk, A. S., & Raudenbush, S. W. (1992). Hierarchical Linear Models:
Applications and Data Analysis Methods. Newbury Park CA: Sage.
harach, A., Carson, P., Fox, S., Muhammad, U. A., Beckett, J., &
Lim, C. G. (2013). Interventions for preschool children at high
risk for ADHD: A comparative effectiveness review. Pediatrics,
131, 1584--1604. http://dx.doi.org/10.1542/peds. 2012-0974
larke, A. R., Barry, A. R., McCarthy, R., & Selikowitz, M. (2001).
Age and sex effects in the EEG: Development of the normal child.
Clinical Neuropsychology, 112, 806--814.
larke, A. R., Barry, R. J., Bond, D., McCarthy, R., &
Selikowitz, M. (2002). Effects of stimulant medications on
the EEG of children with attention-deﬁcit/hyperactivity dis-
order. Psychopharmacology, 164, 277--284. http://dx.doi.org/
10.1007/s00213-002-1205-0
SI.  Moreno-García  et  al.
uPaul, G., Power, T. J., Anastopoulos, A. D., & Reid, R. (1998).
ADHD Rating Scales DSM-IV for parents and teachers. New York
NY: Guilford Press.
uric, N. S., Assmus, J., Gundersen, D., & Elgen, I. B. (2012). Neu-
rofeedback for the treatment of children and adolescents with
ADHD: A randomized and controlled clinical trial using parental
reports. BMC Psychiatry,  12,  107, 1186/1471-244x-12-107.
vans, W.  S., Schultz, K., DeMars, E., & Heather, D. (2011). Effec-
tiveness of the Challenging Horizons After-School Program for
young adolescents with ADHD. Behavior Therapy, 42,  462--474.
http://dx.doi.org/10.1016/j.beth.2010.11.008
abiano, G. A., Pelham, W. E., Coles, E. K., Gnagy, E. M., Chronis-
Tuscano, A., & O’Connor, B. C. (2009). A meta-analysis of behav-
ioral treatments for attention-deﬁcit/hyperactivity disorder.
Clinical Psychology Review, 29,  129--140. http://dx.doi.org/
10.1016/j.cpr.2008.11.001
onzález-Castro, P., Rodríguez, C., López, A., Cueli, M., &
Álvarez, L. (2013). Attention Deﬁcit Hyperactivity Disor-
der, differential diagnosis with blood oxygenation, beta/theta
ratio, and attention measures. International Journal of Clin-
ical and Health Psychology,  13,  101--109. http://dx.doi.org/
10.1016/S1697-2600(13)70013-9
odgson, K., Hutchinson, A. D., & Denson, L. (2014). Nonphar-
macological treatments for ADHD: A meta-analytic review.
Journal of Attention Disorders, 18,  275--282. http://dx.doi.org/
10.1177/1087054712444732
ang, T. (2007). Documenting research in scientiﬁc articles: Guide-
lines for authors. Chest, 131, 628--632.
ofthouse, N. L., Arnold, L. E., Hersch, S., Hurt, E., & deBeus,
R. (2012). A review of neurofeedback treatment for pediatric
ADHD. Journal of Attention Disorders, 16,  351--372. http://dx.
doi.org/10.1177/1087054711427530
oo, S. K., & Makeig, S. (2012). Clinical utility of EEG
in Attention-Deﬁcit/Hyperactivity Disorder: A research
update. Neurotherapeutics,  9, 569--587. http://dx.doi.org/
10.1007/s13311-012-0131-z
eisel, V., Servera, M., Garcia-Banda, G., Cardo, E., & Moreno,
I. (2014). Reprint of neurofeedback and standard pharmaco-
logical intervention in ADHD: A randomized controlled trial
with six-month follow up. Biological Psychology,  95,  116--125,
org/10.1016/j.biopsycho.2013.04.015.
onastra, V. J., Lubar, J. F., & Linden, M. (2001). The development
of a quantitative electroencephalographic scanning process for
attention deﬁcit-hyperactivity disorder: Reliability and validity
studies. Neuropsychology, 15,  136--144.
oreno-García, I., Delgado-Pardo, G., & Roldán-Blasco, C.
(2015). Attention and Response Control in ADHD. Evalu-
ation through Integrated Visual and Auditory Continuous
Performance Test. Spanish Journal of Psychology,  18,  1--14.
http://dx.doi.org/10.1017/sjp.2015.2
ooperative Group, M. T. A. (1999). A 14-month randomized clinical
trial of treatment strategies for attention-deﬁcit/hyperactivity
disorder. The MTA Cooperative Group. Multimodal Treatment
Study of Children with ADHD. Archives of General Psychiatry,
56, 1073--1086.
ICE (2013). Attention deﬁcit hyperactivity disorder (ADHD) Sep.
2008. Last modiﬁed March 2013. Diagnosis and management of
ADHD in children, young people and adults. NICE clinical guide-
line 72. guidance.nice.org.uk/cg72. NICE: London.
grim, G., Kropotov, J., & Hestad, K. (2012). The QEEG theta/beta
ratio in ADHD and normal controls: Sensitivity, speciﬁcity and
behavioral correlates. Psychiatry Reserarch, 198, 482--488.
http://dx.doi.org/10.1016/j.psychres.2011.13.041
eugh, L. J. (2010). A practical guide to multilevel modeling.
Journal of School Psychology, 48,  85--112. http://dx.doi.org/
10.1016/j.jsp.2009.09.002
an Martin, C. R., & Pardo, M. A. (1989). Psicoestadística. Con-
trastes paramétricos y no paramétricos. Madrid: Pirámide.
rapy
S
T
V
W
(2011). Neurofeedback as a treatment for ADHD: A system-Neurofeedback,  pharmacological  treatment,  behavioral  the
Sibley, M. H., Kuriyan, A. B., Evans, S. W.,  Waxmonsky, J. G., &
Smith, B. H. (2014). Pharmacological and psychosocial treat-
ments for adolescents with ADHD: An update systematic review
of the literature. Clinical Psychology Review, 34,  218--232.
http://dx.doi.org/10.1016/j.cpr.2014.02.001
Snyder, S. M., & Hall, J. R. (2006). A meta-analysis of quantita-
tive EEG power associated with attention-deﬁcit hyperactivity
disorder. Journal of Clinical Neurophysiology, 23,  441--456.
http://dx.doi.org/10.1097/01.wnp.0000221363.12503.78
So, C. Y., Leung, P. W.,  & Hung, S. F. (2008). Treatment
effectiveness of combined medication/behavioural treatment
with chinese ADHD children in routine practice. Behaviour
Research and Therapy, 46,  983--992. http://dx.doi.org/
10.1016/j.brat.2008.06.007
Sandford, J. A., & Turner, A. (2000). Integrated visual and audi-
tory continuous performance test manual.  Richmond. VA: Brain
Train.
Spanish National Health System. (2010). Clinical Practice Guideline
on Attention Deﬁcit Hyperactivity Disorder (ADHD) in children
and adolescents. Barcelona: Ministry of Science and Innovation.
Storebø, O. J., Gluud, C., Winkel, P., & Simonsen, E. (2012).
Social-Skills and Parental Training plus Standard Treatment in  Hyperactivity  225
versus Standard Treatment for Children with ADHD- The Ran-
domised SOSTRA Trial. PLoS ONE, 7, 1--8. http://dx.doi.org/
10.1371/journal.pone.0037280
wanson, J. M. (2003). The SNAP-IV. Teacher and Parent Rating
Scale. In A. Fine, & R. Kotkin (Eds.), Therapists´ Guide to Learning
and Attention Disorders (pp. 487--495). San Diego. CA: Academic
Press.
hompson, M., & Thompson, L. (2003). The Neurofeedback Book.
An Introduction to Basic Concepts in Applied Psychophysiology.
Wheat Ridge, Colorado USA: The Association for Applied Psy-
chophysiology and Biofeedback.
an der Oord, S., Prins, P. J. M., Oosterlaan, J., & Emmelkamp, P.
M. G. (2008). Efﬁcacy of methylphenidate, psychosocial treat-
ments and their combination in school-aged children with ADHD:
A meta-analysis. Clinical Psychology Review,  28,  783--800.
http://dx.doi.org/10.1016/j.cpr.2007.10.007
illis, W.  G., Weyandt, L. L., Lubiner, A. G., & Schubart, C. D.atic review of evidence for practice. Journal of Applied School
Psychology,  27,  201--227. http://dx.doi.org/10.1080/15377903.
2011.590746
